Jessica L. Thibaud, Dirkie C. Myburgh, Rebecca D. Sandlin, Kim Y. Fong, Larnelle F. Garnie, Kathryn J. Wicht, David Kuter, David W. Wright, Timothy J. Egan, Katherine A. de Villiers
{"title":"Exploration of Antiplasmodium Chemical Space Identifies New Inhibitors of β-Hematin Formation from Areas of Enrichment","authors":"Jessica L. Thibaud, Dirkie C. Myburgh, Rebecca D. Sandlin, Kim Y. Fong, Larnelle F. Garnie, Kathryn J. Wicht, David Kuter, David W. Wright, Timothy J. Egan, Katherine A. de Villiers","doi":"10.1002/cmdc.202500752","DOIUrl":null,"url":null,"abstract":"<p>The Tres Cantos Antimalarial Set (TCAMS) library is a valuable resource for identifying hits for the antimalarial pipeline. We used principal component analysis (PCA) to explore this tranche of chemical space. Applying a set of 17 two-dimensional (2D) molecular descriptors, the chemical space was mapped in 2D PC space. Thereafter, the locations of known inhibitors and noninhibitors of synthetic hemozoin (<i>β</i>-hematin) formation, a well-established drug target during the asexual blood stage of the <i>Plasmodium falciparum</i> parasite life cycle, were superimposed onto the 2D map and counted. Within the +PC1, −PC2 quadrant, an area of enrichment emerged that could be used to predict the activity of test compounds. A subset of 861 TCAMS compounds (45 inhibitors and 816 noninhibitors) yielded a 27% hit rate when filtered using the enrichment map. Thereafter, 81 diverse compounds with predicted activity were purchased and 20 (25%) were active. <b>B37</b>, which contains a pyrido carbazole scaffold, demonstrated potent <i>β</i>-hematin formation inhibitory activity (IC<sub>50</sub> = 6.4 ± 0.19 μM) as well as noteworthy activity against the chloroquine-sensitive NF54 strain (IC<sub>50</sub> = 0.32 ± 0.03 μM). The PCA enrichment map for <i>β</i>-hematin inhibition is a useful tool for rapid identification of potential hit compounds and may be extended in the future to other antimalarial targets.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":"21 3","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2026-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12908436/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ChemMedChem","FirstCategoryId":"3","ListUrlMain":"https://chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/cmdc.202500752","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
The Tres Cantos Antimalarial Set (TCAMS) library is a valuable resource for identifying hits for the antimalarial pipeline. We used principal component analysis (PCA) to explore this tranche of chemical space. Applying a set of 17 two-dimensional (2D) molecular descriptors, the chemical space was mapped in 2D PC space. Thereafter, the locations of known inhibitors and noninhibitors of synthetic hemozoin (β-hematin) formation, a well-established drug target during the asexual blood stage of the Plasmodium falciparum parasite life cycle, were superimposed onto the 2D map and counted. Within the +PC1, −PC2 quadrant, an area of enrichment emerged that could be used to predict the activity of test compounds. A subset of 861 TCAMS compounds (45 inhibitors and 816 noninhibitors) yielded a 27% hit rate when filtered using the enrichment map. Thereafter, 81 diverse compounds with predicted activity were purchased and 20 (25%) were active. B37, which contains a pyrido carbazole scaffold, demonstrated potent β-hematin formation inhibitory activity (IC50 = 6.4 ± 0.19 μM) as well as noteworthy activity against the chloroquine-sensitive NF54 strain (IC50 = 0.32 ± 0.03 μM). The PCA enrichment map for β-hematin inhibition is a useful tool for rapid identification of potential hit compounds and may be extended in the future to other antimalarial targets.
期刊介绍:
Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies.
ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs.
Contents
ChemMedChem publishes an attractive mixture of:
Full Papers and Communications
Reviews and Minireviews
Patent Reviews
Highlights and Concepts
Book and Multimedia Reviews.